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Abstract  14 
Background: The incidence of liver disease is increasing in the UK and primary care is a key 15 
setting where improvement in the detection and management of liver disease is required. Little 16 
is known about general practitioners’ (GPs) understanding and confidence in detecting liver 17 
disease.  18 
Aim: To explore GPs’ experiences of liver disease with a focus on early detection and 19 
interpretation of liver function tests (LFTs). 20 
Design and setting: Qualitative study employing semi-structured interviews. Purposive sample 21 
of 25 GPs from five study sites. 22 
Method: Telephone and face-to-face interviews. Data were analysed thematically, using a 23 
constant comparative approach. 24 
Results:  Four themes were identified from the data: test requesting behaviour, challenges in 25 
diagnosing disease, access to specialist tests, and guidance and education. Participants’ 26 
descriptions of how they request and interpret LFTs varied widely. Concern over missing 27 
diagnoses was a common reason for requesting blood tests;  patients with mildly abnormal 28 
LFTs and  those at risk of non-alcoholic fatty liver disease (NAFLD) were a particular cause of 29 
concern. GPs saw themselves as generalists, with a reluctance to take on specialist 30 
investigations. Guidelines promoted confidence for some clinicians, but others felt that liver 31 
disease was too complex to be amenable to simple instructions. Most felt that they did not have 32 
access to relevant, focused education on liver disease. 33 
  
Conclusion: Liver disease is not perceived as a priority in primary care. If GPs are to take on a 34 
greater role in identification and management of liver disease, support is needed to promote 35 
awareness, knowledge and confidence.   36 
 37 
Key words: (MeSH headings) Liver diseases; Liver function tests; Early diagnosis; General 38 
Practice; United Kingdom 39 
 40 
How this fits in?  41 
Liver disease is a major cause of premature mortality in the UK; primary care has been 42 
identified as an area where major improvement is required. 43 
This study explores GPs’ understanding and experiences of identifying liver disease. 44 
Our findings add to growing evidence of a lack of confidence amongst GPs in this area, and 45 
identify Non-alcoholic fatty liver disease (NAFLD) as a particular area of diagnostic and 46 
management concern. 47 
Further research should focus on the most effective way of providing support, guidance and 48 
training for GPs in the identification and management of liver disease. 49 
 50 
 51 
Introduction 52 
The incidence of liver disease is increasing faster in the UK than in any other European 53 
country,(1)(2) Liver disease is already one of the leading causes of premature mortality in the 54 
UK, responsible for 61,000 years of working life lost each year. (3)  These rises are linked to 55 
increases in alcohol consumption and obesity. (4, 5)  The Chief Medical Officer and an All Party 56 
Parliamentary group on liver disease have identified early detection as a public health priority, 57 
citing evidence that this will reduce disease progression. (6, 7)  Despite detection and 58 
management of chronic diseases being a major part of the work of general practice, there have 59 
been calls for urgent improvement in primary care for patients with chronic liver disease. (8)   60 
 61 
Early detection of liver disease is a challenge. Many patients have few symptoms until the 62 
condition is advanced, when intervention may be ineffective. Liver function tests (LFTs) are a 63 
panel of blood tests commonly requested in primary care. However, LFTs on their own are a 64 
poor diagnostic tool. Recent guidance from the National Institute for Health and Care Excellence 65 
(NICE) advises against relying on routine blood tests to rule out disease such as NAFLD and 66 
cirrhosis from all causes.(9, 10)  Interpretation of LFT results is not straightforward,(11) with 67 
  
algorithms developed to support general practitioners (GPs) (12, 13) and only very recent 68 
publication of national guidelines to support the interpretation of abnormal liver blood tests. (14)  69 
A recent Lancet Commission on liver disease has highlighted the need to improve expertise and 70 
facilities in primary care to strengthen detection.(3) Current evidence promotes the use of new 71 
investigations to detect the presence and severity of liver disease, such as serum tests for 72 
fibrosis and transient elastography.(15, 16)  However, these tests are not widely available, and 73 
GPs’ understanding of their role in detection and management of liver disease in primary care is 74 
unknown. With multiple, competing priorities, it is not clear that GPs perceive early diagnosis of 75 
liver disease to be an important area for clinical education and service development.  76 
 77 
This paper explores GPs’ experiences of identifying and managing liver disease of all causes, 78 
with a focus on early detection and the interpretation of blood test results. 79 
 80 
Methods 81 
 82 
Design and participants 83 
Qualitative semi-structured interviews were conducted with GPs from five geographical areas in 84 
England (North East and North Cumbria; North West London; Thames Valley and South 85 
Midlands; Yorkshire and Humber; Wessex). Ethical approval for the study was granted by 86 
Newcastle University (Ref 151073). Participants were recruited via Clinical Research Networks 87 
and local networks of GP practices, using email invitations. Purposive sampling in the five areas 88 
was utilised to ensure that we captured a variety of perspectives and varying levels of clinical 89 
experience and knowledge in general practice, hepatology or gastroenterology.  90 
 91 
A semi-structured interview schedule was developed by the research team to cover topics 92 
identified from published literature, including GPs’ experiences of requesting and interpreting 93 
LFTs and the availability of guidelines and educational resources on detection of liver disease. 94 
The interview guide evolved throughout data collection to enable exploration of emerging topics. 95 
When the data were judged to be sufficient and no longer developing in depth and complexity, 96 
recruitment ceased.   Participants were interviewed face-to-face or on the telephone, and all 97 
interviews were audio recorded, and transcribed verbatim. The NVivo 10 software package was 98 
used to manage the data.  99 
 100 
  
Data analysis 101 
The study design was informed by Glaser and Strauss’ constant comparative approach.(17) 102 
Data collection and analysis ran concurrently throughout the study, analysis of early transcripts 103 
informed the interview schedule for later interviews and early transcripts were revisited 104 
throughout the analysis process. Familiarisation with the data involved a detailed reading of the 105 
transcripts. This was followed by line-by-line and highlighting approaches for coding the 106 
data.(18) Field notes were used throughout analysis as part of the reflective process. To ensure 107 
the trustworthiness of the data, a proportion of the transcripts (20%) were coded independently 108 
by three researchers, before comparing and agreeing on themes. The wider research team 109 
were involved in discussions around emerging themes, this included individuals with experience 110 
in general practice, hepatology, and alcohol and health behaviours.  111 
 112 
Findings 113 
Twenty five GPs (12 male and 13 female) took part in interviews; two were conducted face-to-114 
face, and 23 by telephone. Interviews lasted between 15 and 50 minutes.  Participants’ clinical 115 
experience ranged from three years of GP training to over twenty five years in general practice. 116 
Only four participants had undertaken any specialist training in hepatology or gastroenterology. 117 
Practice populations served by the GPs varied widely in size and characteristics, from urban 118 
practices with a high degree of substance misuse to rural practices with primarily elderly 119 
populations. Characteristics of the study participants are shown in Table 1. 120 
 121 
(Table 1 here) 122 
 123 
Four themes were identified from the data: test requesting behaviour, confidence and 124 
challenges in diagnosing disease, access to specialist tests, and guidance and education. In the 125 
following section, quotations are presented to illustrate the majority and any extreme views. 126 
 127 
Test requesting behaviour 128 
All of the interviewees reported that liver function tests (LFTs) were part of routine practice in 129 
primary care. These were often ordered by other members of the primary care team as part of 130 
‘routine health checks’ or to monitor long term medication use, as well as by GPs for 131 
symptomatic patients. Some GPs saw abnormal LFTs as a way to encourage patients to modify 132 
their behaviour, and used them in high risk patients as part of a lifestyle intervention. 133 
 134 
  
“You might do the LFTs just to sort of encourage people, because often, an 135 
abnormal result can make them feel that, actually, there is a problem and they 136 
need to do something about it.” (GP 16, partner, qualified more than 20 years) 137 
 138 
Several interviewees admitted to using LFTs as part of a ‘defensive medicine’ strategy to avoid 139 
missing a serious diagnosis with an undefined problem. As a result, there was a feeling that too 140 
many LFTs were being requested, creating unnecessary work for GPs. This increase in 141 
workload had prompted some GPs to become more cautious, although they acknowledged that 142 
their decisions about when to request LFTs were not necessarily based on evidence. 143 
 144 
“I try to have a reason to do it because I got the sense that you could find an 145 
abnormal test that’s not significant. So I deliberately think about why I need to 146 
do before I do them. So I don't know of the evidence of when we should be 147 
doing them, so no, I don't do them in that way.” (GP 13, partner, qualified more 148 
than 20 years) 149 
 150 
A number of the interviewees indicated that their decision to request LFTs was influenced by 151 
their perception of the potential benefits of treatment. If a possible diagnosis of liver disease 152 
would not affect the patient’s outcome, they felt that testing for it was futile.  153 
 154 
“I’m all for identifying people who have a condition that is going to have an 155 
impact on them, and trying to do something about that, but I don’t know. 156 
Sometimes it feels, fatty liver for example is it...? What is the evidence that you 157 
can make any difference to that? If somebody is obese and has a fatty liver is 158 
there anything specifically an issue about their liver, or actually is it just part of 159 
the whole thing that it needs lifestyle change” (GP 5, partner, qualified more 160 
than 20 years) 161 
 162 
For some patients, participants suggested that efforts might be better focused on lifestyle 163 
intervention rather than testing for specific conditions. 164 
 165 
Confidence and challenges in diagnosing disease 166 
Whilst interviewees reported that they dealt with LFTs on a daily basis, this did not necessarily 167 
mean that they felt confident interpreting the results. Some of the GPs reflected that they were  168 
  
detecting fewer patients with liver disease that is predicted by national statistics. This led to 169 
concerns that they were missing diagnoses.  170 
 171 
“I slightly worry, having done this [interview] that I'm missing some.” (GP 15, 172 
partner, qualified 15 years) 173 
 174 
However, others felt that they were competent at diagnosing liver disease and did not perceive it 175 
as an area where their practice needed improvement.  176 
 177 
“I don’t think it’s an area where GPs are frequently missing the diagnosis, or 178 
delaying the diagnosis. I think, because it’s so easy to get LFTs, and because 179 
most diseases, whether its cancer, hepatitis, or alcoholic liver disease, they’re 180 
pretty prevalent, you know, so we’re used to dealing with them.” (GP 2, partner 181 
qualified for more than 20 years) 182 
 183 
Diagnosis and follow up of patients with NAFLD was identified as a challenge. Concerns related 184 
to identifying disease in high risk groups, and knowing when to refer and how often to follow up. 185 
Some of the interviewees felt that they may be overlooking diagnoses of NAFLD in high risk 186 
groups. Currently, there is no universally approved method of identifying patients with NAFLD in 187 
UK general practice and several of the participants felt this may be contributing to missed 188 
diagnoses.  189 
 190 
“I think we probably miss a lot of liver disease which is non-alcoholic fatty liver 191 
disease, particularly in diabetics. We probably sit and wait on those patients 192 
more than we should be, and I think what we really should be doing is being a 193 
bit more proactive, and calculating a fibro-score, and all the other things, so I 194 
think they’re a group there where we could improve, as well.” (GP 1 - GP 195 
registrar) 196 
 197 
A diagnosis of NAFLD may lead to a referral to secondary care. Participants suggested that 198 
often the outcome of such a referral was lifestyle advice, which they felt could have been offered 199 
in primary care saving specialists’ time for more complex issues. A more confident approach to 200 
such referrals was proposed.  201 
 202 
  
“We are sort of thinking, “God, what should we do? Let’s let the liver 203 
specialists decide”, even though they’re just going, “It’s a fatty liver, cut down 204 
his alcohol, control his cholesterol.” You think, “Okay, I could’ve done that 205 
really. That’s what we were going to do.” So I think giving us more confidence 206 
in managing the simple things, and then the consultants can actually get on 207 
and do the difficult things.” (GP 11, partner qualified 13 years) 208 
 209 
GPs in our study commented that they were unaware of any structured approaches for following 210 
up patients with ‘mild’ NAFLD. This led to concerns that evolving disease may be 211 
underestimated. It was proposed that, in line with other chronic diseases, there should be a 212 
recall system within primary care for patients with NAFLD  meaning this patient group would 213 
receive more standardised care.  214 
 215 
“I guess, and this is what we’re not doing at the moment that perhaps we 216 
should be with our fatty liver patients, you know, our patients who are 217 
diagnosed with fatty liver disease who aren’t being- haven’t needed referral up 218 
or being monitored by secondary care, whether we should have some in-219 
house policy or way of monitoring them every so many years, just to see if 220 
there is any change in their blood testing. Rather than it just being a random 221 
thing, that it should be part of a sort of recall system. We haven’t got that set 222 
up.” (GP 16, partner qualified more than 20 years) 223 
 224 
 225 
Minimally deranged LFTs, predominantly transaminases, are a very common finding in primary 226 
care. However, an abnormal transaminase result does not always reflect the level of the 227 
underlying liver damage. Our participants commented that interpreting minor abnormalities in 228 
LFTs and deciding on a suitable course of action was a challenge, and could be a source of 229 
anxiety.  230 
 231 
 “It’s quite easy to refer when you’ve got really abnormal LFTs and an 232 
abnormal ultrasound. It’s the people that fall in the middle that are the most 233 
difficult so they’re the people with the borderline raised LFTs, with maybe a 234 
little bit of fatty liver on an ultrasound but nothing else. They’re the ones that 235 
are the most difficult. Do you just monitor? Do they still need referral? Are they 236 
  
at risk of future liver disease? I’d say they’re the tricky ones actually.” (GP 23, 237 
salaried, qualified 2 years) 238 
 239 
Access to specialist tests 240 
Alongside the standard LFT panel, most of the GPs in our study were able to make direct 241 
requests for ultrasound scans and extra diagnostic blood tests which are usually referred to as 242 
the ‘liver screen.’ A majority of participants expressed a view that the role of the GP is as a 243 
generalist, and if extra investigations are required to make a diagnosis these should be 244 
requested by secondary care clinicians. Time pressures, alongside lack of specialist knowledge, 245 
were cited as reasons why further investigation was considered inappropriate in the primary 246 
care setting. 247 
 248 
“I think we’ll have to accept our limitations as general practitioners, and if there 249 
is anything more complex that’s coming up, they’re better off seeing the 250 
specialist than having me guess at what the results show, so I’m quite happy 251 
with what we have available.” (GP 7, partner, qualified 10 years) 252 
 253 
The interviewees were prompted during the study to describe what any ‘further tests’ may entail. 254 
Some acknowledged that they were unaware which additional tests may be available.  A small 255 
number of the GPs interviewed suggested that additional investigations would be useful, in 256 
particular expanding the routine blood panel to include aspartate aminotransferase (AST) and 257 
direct access to elastography (fibroscan). However, it was recognised that any increased 258 
responsibility for requesting and interpreting results would need to be accompanied by 259 
education. 260 
 261 
“As I said, we need, which are in the USA, ultrasound elastography, we don’t 262 
have direct access to that, to the ultrasound elastography, so that is something 263 
which might be useful.  But it’s having access, and also, another thing is 264 
educating us to interpret the results” (GP 12, partner, qualified 16 years) 265 
 266 
Guidelines and education 267 
Amongst our study participants there was no universal approach to the use of local or national 268 
guidelines to assist in the diagnosis of liver disease. Some of the GPs were aware of local 269 
guidelines, and used them regularly; others would search for help on national GP resource 270 
  
websites if needed. Several GPs were not aware of any specific local or national guidelines and 271 
a few admitted to knowing of guidelines, but choosing to employ their own systems devised 272 
from experience. 273 
 274 
“I mean, the guidelines say, if you’ve got an ALT more than three times the 275 
upper limit of normal, repeated on one or two more occasions, then that would 276 
be a criteria; but it’s not particularly one that I use, I would tend to monitor 277 
those.” (GP1, GP registrar) 278 
 279 
When guidelines were used, they helped to increase GP confidence in their own diagnostic 280 
ability. These guidelines were perceived to have had greater impact on clinician’s confidence 281 
where they were embedded in routine practice, with computer based prompts or clear flow-282 
charts. 283 
 284 
“It just follows off the pathway, it’s quite a clear flowchart, if this 285 
happens, does that happen, or if the other happened, refer on 286 
based on what their fatty liver disease score would be. So, again, 287 
that would be using national guidance, when to refer. So, quite 288 
clear.” (GP 19, salaried, qualified 2 years) 289 
 290 
However, some interviewees suggested that interpretation of LFTs may not be as amenable to 291 
simple rules of interpretation, because of the variation in what an abnormal result may mean for 292 
the individual.  293 
 294 
“ I don’t know whether it’s possible to say, “If it’s up above this amount you 295 
need to do this or below this…” …  you know the way diabetes has flowcharts, 296 
“If the HbA1c is above this you do and if it’s does this you do this.” You follow 297 
those quite clearly, whereas liver function doesn’t really have an equivalent, 298 
like iron monitoring for warfarin. So for other things we do follow quite strict 299 
guidance, but for liver function we don’t really follow it so strictly. I suppose it’s 300 
because it’s so dependent for each person.” (GP 11, partner, qualified 13 301 
years) 302 
 303 
 304 
  
Most of the GPs interviewed expressed a desire for more  education to help them effectively 305 
identify and manage liver disease. There was a consensus that liver disease was not currently 306 
promoted as a high priority area for primary care. Some participants commented that tailored 307 
education around liver disease was limited.    308 
 309 
“We [GP’s] pick and choose what we learn and therefore things that are easy, 310 
because they’re throwing training at us, which they are for cardiology, for 311 
diabetes and mental health, they’re pouring that down our throats so we’re 312 
jumping at all these things. But there’s only a certain amount of days you have 313 
off to go on training and do things. Liver just hasn’t been there at the front, 314 
therefore I think people who would’ve chosen it but it hasn’t really been 315 
available very much so we’ve not done it. I think that probably is a problem.” 316 
(GP 11, partner, qualified 13 years) 317 
 318 
 319 
Discussion  320 
 321 
Our study suggests that liver disease is not perceived by GPs to be a particularly high priority, 322 
but it is an area where they lack confidence. Concerns were focussed on missing diagnoses 323 
and uncertainty about how to respond to patients with mildly abnormal LFTs or those at risk of 324 
NAFLD.  A reluctance to take on additional specialist investigations appeared to be rooted in 325 
GPs’ perception  of their role as medical generalists. Overall, liver disease was seen as complex 326 
and not a suitable topic for simple guidelines.  327 
 328 
Strengths and limitations 329 
This study describes the perceptions of GPs on the diagnosis of liver disease, and we believe it 330 
is novel in its scope. GPs were offered no financial incentives to participate, yet we found no 331 
difficulty in recruiting from any of the five geographical sites. Interviewees were self-selecting, and 332 
from practices known to local clinical research networks. However, the richness and breadth of 333 
the data imply that this was not a major limitation, with participants displaying a readiness to admit 334 
uncertainty or lack of confidence. Our study was conducted just prior to the publication of UK 335 
NICE guidelines on both NAFLD and cirrhosis.(9,10) These documents advocated for change to 336 
current practice. Participants may have been aware that guidelines were in development, but 337 
  
there was no time for them to have influenced experiences of diagnosing liver disease in primary 338 
care.  339 
 340 
Comparison with existing literature 341 
Our findings of GPs’ reported test requesting behaviour are consistent with those reported in the 342 
qualitative arm of a large study looking at testing strategies for liver disease in primary care.(12) 343 
However, that study was focused on test ordering behaviour, and unlike ours, did not explore in 344 
any detail GPs’ experiences of diagnosing liver disease. The use of tests to change patients’ 345 
behaviours, the defensive nature of testing and the feeling that tests were requested too often, 346 
were common themes with our work. Our findings support the recent Lancet report, which 347 
suggests that primary care clinicians require clear guidance on the use of LFTs and the need for 348 
specialist referral.(3) 349 
 350 
A recent study in North America explored primary care physicians’ awareness of, and current 351 
practice related to NAFLD.(19) Knowledge of diagnostic tools and understanding of the difference 352 
between ‘fatty liver’ and more progressive disease were found to be poor, although this brief on-353 
line survey was unable to explore the reasons behind the findings. Several GPs in our study 354 
indicated that NAFLD was an area they found challenging; in particular, knowing how best to 355 
assess risks and follow up patients. Clinicians suggested that referral often resulted only in 356 
lifestyle advice, which they felt could be offered in primary care. Other work beyond the UK has 357 
also identified NAFLD as an area where enhancing knowledge in primary care practice may be 358 
helpful.(20, 21)  359 
 360 
Difficulties  over interpretation of minimally deranged liver function tests may be due in part to the 361 
well documented discordance between blood test abnormalities and extent of liver damage. In 362 
other conditions managed by GPs, the relationship between abnormal blood tests, clinical 363 
decision-making and pathology is often more clear cut (e.g. in chronic kidney disease). GPs also 364 
reported varying use of guidance when managing liver disease. In contrast to other chronic 365 
conditions (22), much local and national guidance on liver disease is focused on aetiological 366 
factors such as alcohol.(23) The relevance to patients with liver disease of different aetiology may 367 
not be apparent, even when the recommended management pathway is still appropriate.  368 
 369 
 370 
 371 
  
Implications for research/practice 372 
Our findings suggest that liver disease should be a target for improved practice in primary care 373 
and that GPs would be receptive to greater support and the promotion of a standardised 374 
approach to investigation and management. This will require adequate resourcing and a better 375 
understanding of precisely how to improve practice in this area. It is important to acknowledge 376 
that many determinants of the rise in chronic liver disese are social and political, and for action 377 
by GPs to be effective, it will need to be part of a broader public health strategy.  Work is 378 
underway, (6, 7,8, 14) but the development of up to date guidance, clinical tools and educational 379 
initiatives is relatively recent (9, 10, 14) Many GPs do not have access to recommended non-380 
invasive tests (e.g. transient elastography and blood biomarkers), and this will need to be 381 
addressed if the guidance is to be implemented. (9, 10)   382 
 383 
Early intervention can be effective for all the main causes of liver disease, including NAFLD,(24) 384 
alcoholic liver disease, (25, 26) and viral hepatitis. Targeted, brief interventions are supported by 385 
a growing body of evidence, (27,28) curative treatments have been developed for hepatitis C, and 386 
new anti-fibrotic medication will soon be widely available for all cause liver fibrosis.(29) Crucially, 387 
all of these depend on awareness and early detection in primary care, and this is an area that 388 
urgently requires further research and development.   389 
 390 
 391 
 392 
 393 
Funding This study was funded by the NIHR School for Primary Care 394 
Disclaimer The views expressed in this paper are those of the authors and not necessarily 395 
those of the NIHR, the NHS or the Department of Health.  396 
Contributions BH, EK, MH, JO, CE designed the study. HS carried out the interviews. HS 397 
undertook the main analysis supported by BH and HJ. HS, HJ, and BH drafted the manuscript, 398 
and all authors commented and approved the final version.   399 
Ethical approval The study was approved by the Health Research Authority and Newcastle 400 
University Research Ethics Committee (Ref 188275) 401 
Competing interests None declared 402 
Acknowledgements We extend our thanks to the GPs who generously gave their time to 403 
participate in this study. 404 
 405 
  
References 406 
 407 
 408 
1.European Health for All database (HFA-DB) [Internet]. 2016 [cited 2018 Feb 5]. Available 409 
from: http://www.euro.who.int/en/data-and-evidence/databases/european-health-for-all-410 
database-hfa-db 411 
 412 
2.Liver disease: applying All Our Health - GOV.UK [Internet]. [cited 2018 Mar 12]. Available 413 
from: https://www.gov.uk/government/publications/liver-disease-applying-all-our-health/liver-414 
disease-applying-all-our-health 415 
 416 
3.Williams R, Alexander G, Armstrong I, et al. Disease burden and costs from excess alcohol 417 
consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on 418 
Liver Disease in the UK. Lancet. 2017 Nov 28; 419 
 420 
4.Liu B, Balkwill A, Reeves G, Beral V, Million Women Study Collaborators. Body mass index 421 
and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010 Mar 422 
11;340:c912. 423 
 424 
5.Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on 425 
liver disease: analysis of data from two prospective cohort studies. BMJ. 2010 Mar 426 
11;340:c1240. 427 
 428 
6.Chief Medical Officer annual report: surveillance volume 2012 - Publications - GOV.UK 429 
[Internet]. [cited 2018 Feb 5]. Available from: https://www.gov.uk/government/publications/chief-430 
medical-officer-annual-report-surveillance-volume-2012 431 
  432 
7.Liver Inquiry 2014 | All-Party Parliamentary Group on Liver Health [Internet]. [cited 2018 Feb 433 
5]. Available from: http://www.appghep.org.uk/liver-inquiry-2014/ 434 
 435 
8.Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for 436 
attaining excellence in health care and reducing premature mortality from lifestyle issues of 437 
excess consumption of alcohol, obesity, and viral hepatitis. The Lancet. 2014;384(9958):1953-438 
97. 439 
 440 
9.Non-alcoholic fatty liver disease (NAFLD): assessment and management | Guidance and 441 
guidelines | NICE [Internet]. [cited 2016 Sep 5]. Available 442 
from: https://www.nice.org.uk/guidance/ng49 443 
 444 
10.Cirrhosis in over 16s: assessment and management | Guidance and guidelines | NICE 445 
[Internet]. [cited 2016 Sep 5]. Available from: https://www.nice.org.uk/guidance/ng50 446 
 447 
11.Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests 448 
dealt with in primary care? Audit of yield and impact. BMJ. 2001 Feb 3;322(7281):276–8. 449 
 450 
 451 
  
12. Lilford RJ, Bentham L, Girling A, et al. Birmingham and Lambeth Liver Evaluation Testing 452 
Strategies (BALLETS): a prospective cohort study. Health Technol Assess. 2013 Jul ;17(28):i-453 
307.  454 
 455 
13. McLernon DJ, Donnan PT, Sullivan FM, et al. Prediction of liver disease in patients whose 456 
liver function tests have been checked in primary care: model development and validation using 457 
population-based observational cohorts. BMJ Open. 2014 Jun 2; 4(6).  458 
 459 
14. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal 460 
liver blood tests. Gut. 2017; Nov 9; gutjnl-2017-314924. 461 
  462 
15. Sheron N, Moore M, Ansett S, Parsons C, Bateman A. Developing a “traffic light” test with 463 
potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Br J Gen 464 
Pract. 2012 Sep;62(602):e616-624. 465 
 466 
 467 
16.Harman DJ, Ryder SD, James MW, et al. Direct targeting of risk factors significantly 468 
increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study 469 
utilising transient elastography. BMJ Open. 2015;5(4):e007516. 470 
 471 
17.Strauss, A.L. and Corbin, J. (1998) Basics of Qualitative Research: Grounded Theory 472 
Procedures and Techniques, 2nd edn. London: Sage, 1998.  473 
 474 
 475 
18.Van Manen M. Practicing phenomenological writing. Phenomenology+ Pedagogy. 476 
1984;2(1):36-69. 477 
 478 
19. Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis 479 
and associated practice patterns of primary care physicians and specialists. BMC Research 480 
Notes. 2016;9:157.  481 
 482 
20. Said A, Gagovic V, Malecki K, et al. Primary care practitioners survey of non-alcoholic fatty 483 
liver disease. Ann Hepatol. 2013 Oct;12(5):758–65. 484 
 485 
21. Grattagliano I, D’Ambrosio G, D’Ambrozio G, et al. Improving nonalcoholic fatty liver 486 
disease management by general practitioners: a critical evaluation and impact of an educational 487 
training program. J Gastrointestin Liver Dis. 2008 Dec;17(4):389–94. 488 
 489 
22. Chronic kidney disease in adults: assessment and management | Guidance and guidelines | 490 
NICE [Internet]. [cited 2018 Mar 12]. Available from: https://www.nice.org.uk/guidance/cg182 491 
 492 
23. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and 493 
alcohol dependence | Guidance and guidelines | NICE [Internet]. [cited 2018 Mar 12]. Available 494 
from: https://www.nice.org.uk/guidance/cg115 495 
 496 
  
24. Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge 497 
for general practitioners and important burden for health authorities? Primary Care Diabetes. 498 
2010 Oct;4(3):129–37.  499 
 500 
25.Verrill C, Smith S, Sheron N. Are the opportunities to prevent alcohol related liver deaths in 501 
the UK in primary or secondary care? A retrospective clinical review and prospective interview 502 
study. Substance abuse treatment, prevention, and policy. 2006;1(1):16. 503 
 504 
26.Eyles C, Moore M, Sheron N, et al. Acceptability of screening for early detection of liver 505 
disease in hazardous/harmful drinkers in primary care. Br J Gen Pract. 2013;63(613):e516-e22. 506 
  507 
27. Kaner EFS, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions in 508 
primary care populations. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: 509 
CD004148.  510 
 511 
28. Hallsworth K, Avery L, Trenell MI. Targeting Lifestyle Behavior Change in Adults with 512 
NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Current 513 
Gastroenterology Reports. 2016;18:11.  514 
 515 
29. Sumida Y, Yoneda M. Current and future pharmacological therapies for 516 
NAFLD/NASH. Journal of Gastroenterology. 2018;53(3):362-376.  517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
  
Table 1: Characteristics of study participants 538 
Characteristic Number of 
participants 
Sex 
o Male 
o Female 
 
12 
13 
 
Years of experience as GP 
o <5 
o 5-15 
o 16-25 
o >26 
 
5 
10 
9 
1 
 
Gastroenterology experience or training 
o Yes 
o No 
 
4 
21 
 
Size of practice (registered patients) 
o <5000 
o 5-10,000 
o 10,000 – 15,000 
o >15,000 
 
 
5 
9 
9 
2 
Area of England (NHS regions) 
o North West London 
o Wessex 
o North East and Cumbria 
o Yorkshire 
o Thames Valley and South Midlands 
 
7 
8 
5 
1 
4 
 
 539 
